Skip to main content

Angion Biomedica Corp. (ANGN)

NASDAQ: ANGN · Delayed Price · USD
9.87 -0.65 (-6.18%)
Sep 20, 2021 4:00 PM EDT - Market closed
Market Cap290.24M
Revenue (ttm)2.20M
Net Income (ttm)n/a
Shares Out29.80M
EPS (ttm)-4.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume218,507
Open10.13
Previous Close10.52
Day's Range9.54 - 10.43
52-Week Range9.03 - 26.30
Betan/a
Analystsn/a
Price Target59.33 (+501.1%)
Est. Earnings DateNov 11, 2021

About ANGN

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops ANG-3070, a tyrosine kinase inhibitor and rho kinase 2 inhibitors for fibrotic diseases; and CYP11B2, an aldosterone synt...

IndustryBiotechnology
IPO DateFeb 5, 2021
Employees72
Stock ExchangeNASDAQ
Ticker SymbolANGN
Full Company Profile

Financial Performance

In 2020, ANGN's revenue was $2.88 million, an increase of 93.68% compared to the previous year's $1.49 million. Losses were -$80.11 million, 97.0% more than in 2019.

Financial Statements

News

Angion Hosting Research & Development Day on ANG-3070 for the Treatment of Lung and Kidney Fibrosis

UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma...

1 week ago - GlobeNewsWire

Angion to Participate in Upcoming September Investment Conferences

UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel smal...

2 weeks ago - GlobeNewsWire

Angion Biomedica Shares Moving Higher On Encouraging Results From Early Stage Trial Of Fibrotic Disease Candidate

Angion Biomedica Corp (NASDAQ: ANGN) has announced positive results from its Phase 1 study in healthy volunteers for ANG-3070 for fibrotic diseases.  In the 97-volunteer trial, ANG-3070 achieved drug ex...

1 month ago - Benzinga

Angion Reports Positive Results from Phase 1 Healthy Volunteer Study for ANG-3070 and FDA Authorization to Initiate P...

UNIONDALE, N.Y., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small...

1 month ago - GlobeNewsWire

Angion Announces Results from the Phase 2 ALI-201 Study in Patients with COVID-19 Associated Pneumonia

UNIONDALE, N.Y., June 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel smal...

2 months ago - GlobeNewsWire

Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results

UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small ...

4 months ago - GlobeNewsWire

Vifor Pharma and Angion announce completion of enrollment in phase-II study of ANG-3777 for cardiac-surgery associate...

ST. GALLEN, Switzerland & UNIONDALE, NY--(BUSINESS WIRE)--Regulatory News: Vifor Pharma and Angion Biomedica Corp. (NASDAQ: ANGN), today announced completion of enrollment for Angion's AKI-002-15 study,...

4 months ago - Business Wire

Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated...

Topline data expected in the second half of 2021 Topline data expected in the second half of 2021

4 months ago - GlobeNewsWire

Angion Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results

UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma...

5 months ago - GlobeNewsWire

Angion Completes Enrollment in Phase 2 Study of ANG-3777 for Acute Lung Injury in Patients with COVID-19 Associated P...

Topline data expected in the first half of 2021 Topline data expected in the first half of 2021

5 months ago - GlobeNewsWire

Angion Announces Partial Waiver of Certain Lock-up Restrictions

UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel sma...

6 months ago - GlobeNewsWire

Angion to Participate in Upcoming March Investment Conferences

UNIONDALE, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel smal...

6 months ago - GlobeNewsWire

Angion Biomedica Corp. Announces Closing of $117 Million Initial Public Offering and Concurrent Private Placement, In...

UNIONDALE, N.Y., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of n...

7 months ago - GlobeNewsWire

Angion Biomedica Corp. Announces Pricing of Initial Public Offering of Common Stock and Concurrent Private Placement

UNIONDALE, N.Y., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (Angion) (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development and commercialization of no...

7 months ago - GlobeNewsWire

Phase 3 biotech Angion Biomedica files for a $75 million IPO

Angion Biomedica, a Phase 3 biotech developing small molecule therapies for acute organ injuries, filed on Friday with the SEC to raise up to $75 million in an initial public offering. The company had p...

8 months ago - NASDAQ

Angion Biomedica IPO Registration Document (S-1)

Angion Biomedica Corp. has filed to go public with an IPO on the NASDAQ.

8 months ago - SEC